Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Alnylam Pharmaceuticals's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 64.52.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Alnylam Pharmaceuticals's liquidation value for the
three
months ended in Jun. 2026 was MXN-2,851 Mil.
Alnylam Pharmaceuticals (MEX:ALNY) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Alnylam Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alnylam Pharmaceuticals Change In Receivables Related Terms
Alnylam Pharmaceuticals Change In Receivables Historical Data
* Premium members only.
The historical data trend for Alnylam Pharmaceuticals's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alnylam Pharmaceuticals Change In Receivables Chart
Alnylam Pharmaceuticals Change In Receivables Calculation
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-6,560 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Receivables of MXN-6,560 Mil mean?
Alnylam Pharmaceuticals (MEX:ALNY) has a Change In Receivables of MXN-6,560 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Alnylam Pharmaceuticals and its competitors.
Is Alnylam Pharmaceuticals' Change In Receivables too high?
Alnylam Pharmaceuticals' current Change In Receivables is MXN-6,560 Mil. Overall, Alnylam Pharmaceuticals has a GF Score™ of 65/100, reflecting its overall financial health beyond just this single metric.
How does Alnylam Pharmaceuticals' Change In Receivables compare to RPRX and INSM?
Alnylam Pharmaceuticals' Change In Receivables of MXN-6,560 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Alnylam Pharmaceuticals and its competitors. Alnylam Pharmaceuticals's current Change In Receivables is MXN-6,560 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alnylam Pharmaceuticals stock overvalued right now?
Alnylam Pharmaceuticals (MEX:ALNY) has a current Change In Receivables of MXN-6,560 Mil. The stock's GF Value™ is MXN11,444.89, compared to a current price of MXN5,549.00 — trading 51.5% below its estimated fair value. The current Change In Receivables is MXN-6,560 Mil. Alnylam Pharmaceuticals' overall GF Score™ is 65/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Alnylam Pharmaceuticals (MEX:ALNY), the current Change In Receivables is MXN-6,560 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alnylam Pharmaceuticals (MEX:ALNY) Overvalued in 2026?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals stock appears to be undervalued.
The current stock price of MXN5,549.00 is trading 51.5% below its estimated GF Value™ of MXN11,444.89.
Key valuation signals for MEX:ALNY:
Change In Receivables: MXN-6,560 Mil
GF Value™: MXN11,444.89 vs. price of MXN5,549.00 (51.5% below fair value)
No single metric tells the full story. See the MEX:ALNY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
65GF Score
Get the complete analysis for MEX:ALNY
Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ALNY has been successfully added to your 
